Isolation, Characterization, Proliferation and Differentiation of Synovial Membrane-derived Mesenchymal Stem Cells (SM-MSCs) from Osteoarthritis Patients

Marlina Marlina, Rizki Rahmadian, Armenia Armenia, Wahyu Widowati, Rizal Rizal, Hanna Sari Widya Kusuma, Satrio Haryo Benowo Wibowo, Wahyu Setia Widodo, Ika Adhani Sholihah

Abstract


Background: Mesenchymal stem cells (MSCs) are the cells which have high renewal capacity and and are capable for differentiating into some types of cells. MSCs can be obtained from several tissues including bone marrow, synovial membrane, blood, adipose tissue and periosteum. The proliferation and self-repair ability of MSCs are the advantages to use as stem cells-based therapy of various diseases. The aim of this study was to determine the differentiation, characterization and proliferation of synovial membrane-derived MSCs (SM-MSCs).

Materials and Methods: The cells proliferation capacity was determined by cell counting using trypan blue, characterization of MSCs (cluster of differentiation (CD)90, CD11b, CD73, CD34, CD19, CD45, CD105 and human leukocyte antigen-DR isotype (HLA-DR)) using flow cytometry analysis, and differentiation capability into three lineage cells was determined with red alcian blue, oil red O and alizarin staining.

Results: The type culture of SM-MSCs was adherent and showed positive CD44, CD105, CD73, CD90 and negative of CD19, HLA-DR, CD11b, CD45, CD34 surface marker. Based on the result, SM-MSCs P3 showed differentiation potency into adipogenic, chondrogenic, and osteogenic lineage cells. The population doubling time of SM-MSCs has increased from P3 to P8. The population doubling time of SM-MSCs P3 was 1.69 days and SM-MSCs P8 was 3.64 days.

Conclusion: The results indicated that SM-MCSCs from osteoarthritis patients are able to differentiate into osteocytes, chondrocytes, adipocytes and highly express of CD105, CD73, CD90, CD44 and negative for CD34, CD45, CD14, CD19.

Keywords: synovial membrane, mesenchymal stromal cells, adipocyte, chondrocyte, osteocyte


Full Text:

PDF

References


Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012; 64(6): 1697-707, CrossRef.

Teitel AD, Zieve D. Medline Plus Medical Encycolpedia: Osteoarthritis. Bethesda: National Institutes of Health; 2011.

World Health Organization [Internet]. Chronic diseases and health promotion: chronic rheumatic conditions [updated 2012; cited 2019 Mar 30]. Available from: https://www.who.int/.

Ahmed U, Anwar A, Savage RS, Costa ML, Mackay N, Filer A, et al. Biomarkers of early stage osteoarthritis, rheumatoid Arthritis and Musculoskeletal Health. Sci Rep. 2015; 5: 9259, CrossRef.

Brandt, KD. Non-surgical treatment of osteoarthritis: a half century of ‘‘dvances’’. Ann Rheum Dis. 2004; 63(2): 117-22, CrossRef.

Khairani Y, Eryasni H, Nindya A. Hubungan Umur, Jenis Kelamin, IMT, dan Aktivitas Fisik Dengan Kejadian Osteoathritis Lutut. Jambi: Fakultas Kedokteran dan Ilmu Kesehatan Universitas Jambi; 2013, article.

Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001; 27(2): 269-81, CrossRef.

Kremers HM, Nicola P, Crowson CS, O'Fallon WM, Gabriel SE. Therapeutic strategies in rheumatoid arthritis over a 40-year period. J Rheumatol. 2004; 31(12): 2366-73, article.

Leong DJ, Choudhury M, Hanstein R, Hirsh DM, Kim SJ, Majeska RJ, et al. Green tea polyphenol treatment is chondroprotective, anti-inflammatory and palliative in a mouse post-traumatic osteoarthritis model. Arthritis Res Ther. 2014; 16(6): 508-514, CrossRef.

Andriolo L, Merli G, Filardo G, Marcacci M, Kon E. Failure of autologous chondrocyte implantation. Sports Med Arthrosc Rev. 2017; 25(1): 10-8, CrossRef.

Vanlauwe J, Saris DB, Victor J, Almqvist KF, Bellemans J, Luyten FP, et al. Five-year outcome of characterized chondrocyte implantation versus microfracture for symptomatic cartilage defects of the knee: early treatment matters. Am J Sports Med. 2011; 39(12): 2566–2574, CrossRef.

Fuchs E, Segre JA. Stem cells: a new lease on life. Cell. 2000; 100(1): 143-55, CrossRef.

Widowati W, Wijaya L, Murti H, Widyastuti H, Agustina D, Laksmitawati DR, et al. Conditioned medium from normoxia (WJMSCs-norCM) and hypoxia-treated WJMSCs (WJMSCs-hypoCM) in inhibiting cancer cell proliferation. Biomarkers Genomic Med. 2015; 7(1): 8-17, CrossRef.

Widowati W, Jasaputra DK, Sumitro SB, Widodo MA, Yaprianto K, Bachtiar I. Potential of unengineered and engineered wharton’s jelly mesenchymal stem cells as cancer inhibitor agent. Immun Endoc Metab Agents in Med Chem. 2015; 15: 128-37, CrossRef.

Ruiz M, Cosenza S, Maumus M, Jorgensen C, Noël D. Therapeutic application of mesenchymal stem cells in osteoarthritis. Expert Opin Biol Ther. 2016; 16(1): 33-42, CrossRef.

Ayatollahi M, Talaei-Khozani T, Razmkhah M. Growth suppression effect of human mesenchymal stem cells from bone marrow, adipose tissue, and wharton’s jelly of umbilical cord on PBMCs. Iran J Basic Med Sci. 2016; 19(2): 145-53, article.

Sato M, Uchida K, Nakajima H, Miyazaki T, Guerrero AR, Watanabe S, et al. Direct transplantation of mesenchymal stem cells into the knee joints of hartley strain guinea pigs with spontaneous osteoarthritis. Arthritis Res Ther. 2012; 14(1): R31, CrossRef.

Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. J Orthop Res. 2009; 27(12): 1675-80, CrossRef.

Sousa EB, Casado PL, Neto VM, Duarte MEL, Aguiar DP. Synovial fluid and synovial membrane mesenchymal stem cells: latest discoveries and therapeutic perspectives. Stem Cell Res Ther. 2012; 5(5): 112, CrossRef.

Sugita N, Moriguchi, Y, Sakaue M, Hart DA, Yasui Y, Koizumi K, et al. Optimization of human mesenchymal stem cell isolation from synovial membrane: Implications for subsequent tissue engineering effectiveness. Regen Ther. 2016; 5: 79-85, CrossRef.

Block TJ, Marinkovic M, Tran ON, Gonzalez AO, Marshall A, Dean DD, et al. Restoring the quantity and quality of elderly human mesenchymal stem cells for autologous cell-based therapies. Stem Cell Res Ther. 2017; 8(1): 239, CrossRef.

Widowati W, Wijaya L, Bachtiar I, Gunanegara R, Sugeng SU, Irawan YA, et al. Effect of oxygen tension on proliferation and characteristics of wharton’s jelly-derived mesenchymal stem cells. Biomarkers Genomic Med. 2014; 6: 43-8, CrossRef.

Ha JW, Kim JA, Ha CW. Do the fibroblasts contained in early passage MSC population adversely affect the characteristics of stem cell population obtained from human placenta? Int J Stem Cells. 2012; 5(2): 89-95, CrossRef.

Fickert S, Fiedler J, Brenner RE. Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. Osteoarthritis Cartilage. 2003; 11(11): 790-800, CrossRef.

Widowati W, Murti H, Jasaputra DK, Sumitro SB, Widodo MA, Fauziah N, et al. Selective cytotoxic potential of IFN-γ and TNF-α on breast cancer cell lines (T47D and MCF7). Asian J Cell Biol. 2016; 11(1): 1-12, CrossRef.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8 (4): 315-7, CrossRef.

Trujillo NA, Popat KC. Increased adipogenic and decreased chondrogenic differentiation of adipose derived stem cells on nanowire surfaces. Materials (Basel). 2014; 7(4): 2605-30, CrossRef.

Jin HJ, Bae YK, Kim M, Kwon SK, Jeon HB, Choi SJ, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci. 2013; 14(9): 17986-8001, CrossRef.




DOI: https://doi.org/10.21705/mcbs.v4i2.100

Indexed by:

                     

                    

                    


Cell and BioPharmaceutical Institute